These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Modulating native GABA Kallay L; Keskin H; Ross A; Rupji M; Moody OA; Wang X; Li G; Ahmed T; Rashid F; Stephen MR; Cottrill KA; Nuckols TA; Xu M; Martinson DE; Tranghese F; Pei Y; Cook JM; Kowalski J; Taylor MD; Jenkins A; Pomeranz Krummel DA; Sengupta S J Neurooncol; 2019 May; 142(3):411-422. PubMed ID: 30725256 [TBL] [Abstract][Full Text] [Related]
3. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma. Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591 [TBL] [Abstract][Full Text] [Related]
4. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice. Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543 [TBL] [Abstract][Full Text] [Related]
5. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma. Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662 [TBL] [Abstract][Full Text] [Related]
7. Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721 [TBL] [Abstract][Full Text] [Related]
8. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Li Y; Guessous F; Johnson EB; Eberhart CG; Li XN; Shu Q; Fan S; Lal B; Laterra J; Schiff D; Abounader R Lab Invest; 2008 Feb; 88(2):98-111. PubMed ID: 18059365 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395 [TBL] [Abstract][Full Text] [Related]
10. A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors. Staal JA; Pei Y; Rood BR Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775567 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120 [TBL] [Abstract][Full Text] [Related]
12. NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. Fiaschetti G; Schroeder C; Castelletti D; Arcaro A; Westermann F; Baumgartner M; Shalaby T; Grotzer MA Acta Neuropathol Commun; 2014 Apr; 2():39. PubMed ID: 24708907 [TBL] [Abstract][Full Text] [Related]
13. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Weeraratne SD; Amani V; Neiss A; Teider N; Scott DK; Pomeroy SL; Cho YJ Neuro Oncol; 2011 Feb; 13(2):165-75. PubMed ID: 21177782 [TBL] [Abstract][Full Text] [Related]
14. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813 [TBL] [Abstract][Full Text] [Related]
15. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Weeraratne SD; Amani V; Teider N; Pierre-Francois J; Winter D; Kye MJ; Sengupta S; Archer T; Remke M; Bai AH; Warren P; Pfister SM; Steen JA; Pomeroy SL; Cho YJ Acta Neuropathol; 2012 Apr; 123(4):539-52. PubMed ID: 22402744 [TBL] [Abstract][Full Text] [Related]
16. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541 [TBL] [Abstract][Full Text] [Related]
17. Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma. Zomerman WW; Plasschaert SLA; Conroy S; Scherpen FJ; Meeuwsen-de Boer TGJ; Lourens HJ; Guerrero Llobet S; Smit MJ; Slagter-Menkema L; Seitz A; Gidding CEM; Hulleman E; Wesseling P; Meijer L; van Kempen LC; van den Berg A; Warmerdam DO; Kruyt FAE; Foijer F; van Vugt MATM; den Dunnen WFA; Hoving EW; Guryev V; de Bont ESJM; Bruggeman SWM Cell Rep; 2018 Mar; 22(12):3206-3216. PubMed ID: 29562177 [TBL] [Abstract][Full Text] [Related]
18. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models. Rodriguez-Blanco J; Salvador AD; Suter RK; Swiderska-Syn M; Palomo-Caturla I; Kliebe V; Shahani P; Peterson K; Turos-Cabal M; Vieira ME; Wynn DT; Howell AJ; Yang F; Ban Y; McCrea HJ; Zindy F; Danis E; Vibhakar R; Jermakowicz A; Martin V; Coss CC; Harris BT; de Cubas A; Chen XS; Barnoud T; Roussel MF; Ayad NG; Robbins DJ J Clin Invest; 2024 Jun; 134(15):. PubMed ID: 38885332 [TBL] [Abstract][Full Text] [Related]
19. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression. Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491 [TBL] [Abstract][Full Text] [Related]
20. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]